Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HARMONY

Financiado

Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in Hem...

Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY Sofia ref. 116026 Despite significant recent progress in the field of hematological malignancies (HMs), with increasing survival rates and improvement in quality of life, many children and adults with HMs still die from these disorders or experienc... ver más

30/06/2023

FUNDACION INSTITUT...

42M€

Presupuesto del proyecto: 42M€

Líder del proyecto

FUNDACION INSTITUTO ESTUDIOS CIENCIAS DE LA S... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 11M€

Ver 57 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-06-30

IMI2-2015-06-04: Development of an outcomes-focused...

I+D

Cerrada hace 8 años

0% 48% 100%

57 Participantes

FUNDACION INSTITUTO ESTUDIOS...

7.00M€ | Lider

CEGASA PORTABLE ENERGY

326.07K€ | Participante

INFN

N.D. | Participante

SYNAPSE

500.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 78 meses Fecha Inicio: 2016-12-22
Fecha Fin: 2023-06-30

Líder del proyecto

FUNDACION INSTITUTO ESTUDIOS CIENCIAS DE LA S... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 11M€

Presupuesto del proyecto 42M€

Descripción del proyecto Despite significant recent progress in the field of hematological malignancies (HMs), with increasing survival rates and improvement in quality of life, many children and adults with HMs still die from these disorders or experience disabling complications. Therefore, improvement of health care of HMs is an unmet medical need. Thus, it is important to define and align standard and efficient sets of HMs outcomes to measure and evaluate HM data for clinical decisions, long term risk/benefit profile, reimbursement, value analysis, and clinical trials design. Improving outcome measures and endpoint definitions by taking into account real-life data and differences in cross-national healthcare practice will undoubtedly result in an optimized, sustainable and effective treatment delivery, as well as in desirable and innovative accelerated pathways for novel drug availability. All these challenges will be addressed within a pan-EU perspective by HARMONY (Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY), a comprehensive public-private European consortium of excellence. HARMONY consortium is made up of 51 partners: 44 participants from 10 European countries and 7 pharmaceutical companies from the EFPIA. HARMONY aims to assemble, assess, connect, and analyze heterogeneous HM patient derived Big Data sets to define sets of outcome indicators that can be used for decision-making by key healthcare stakeholders. The consortium will orchestrate leading experts and working cooperative groups in HMs, European study alliances, pharmaceutical market leaders, patient advocacy groups, HTA and regulatory agencies, to: (i) optimize Europe-wide data collection and create a high-quality HM data repository for further explorative studies; (ii) establish a clinical data-sharing platform that empowers clinicians, patients and policy stakeholders to improve decision-making procedures and identify appropriate treatments to patients with HMs

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores